PubMed

High-density lipoprotein particle size and concentration and coronary risk.

El Harchaoui K, Arsenault BJ, Franssen R, Després JP, Hovingh GK, Stroes ES, Otvos JD, Wareham NJ, Kastelein JJ, Khaw KT, Boekholdt SM.

Ann Intern Med. 2009 Jan 20;150(2):84-93.PMID: 19153411 [PubMed - indexed for MEDLINE]Related articlesFree article

Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins.

El Harchaoui K, Akdim F, Stroes ES, Trip MD, Kastelein JJ.

Am J Cardiovasc Drugs. 2008;8(4):233-42. Review.PMID: 18690757 [PubMed - indexed for MEDLINE]Related articles

Cholesterol gene polymorphisms and cardiovascular events.

Vergeer M, El-Harchaoui K, Stroes ES.

N Engl J Med. 2008 Jul 3;359(1):92; author reply 93. No abstract available. PMID: 18596280 [PubMed - indexed for MEDLINE]Related articles

The role of CETP inhibition in dyslipidemia.

El Harchaoui K, van der Steeg WA, Stroes ES, Kastelein JJ.

Curr Atheroscler Rep. 2007 Aug;9(2):125-33. Review.PMID: 17877921 [PubMed - indexed for MEDLINE]Related articles

Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk.

van der Steeg WA, Boekholdt SM, Stein EA, El-Harchaoui K, Stroes ES, Sandhu MS, Wareham NJ, Jukema JW, Luben R, Zwinderman AH, Kastelein JJ, Khaw KT.

Ann Intern Med. 2007 May 1;146(9):640-8.PMID: 17470832 [PubMed - indexed for MEDLINE]Related articlesFree article

Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.

El Harchaoui K, van der Steeg WA, Stroes ES, Kuivenhoven JA, Otvos JD, Wareham NJ, Hutten BA, Kastelein JJ, Khaw KT, Boekholdt SM.

J Am Coll Cardiol. 2007 Feb 6;49(5):547-53. Epub 2007 Jan 22.PMID: 17276177 [PubMed - indexed for MEDLINE]Related articles

Increasing high-density lipoprotein cholesterol through cholesteryl Ester transfer protein inhibition: a next step in the fight against cardiovascular disease?

Van der Steeg WA, El-Harchaoui K, Kuivenhoven JA, Kastelein JJ.

Curr Drug Targets Cardiovasc Haematol Disord. 2005 Dec;5(6):481-8. Review.PMID: 16503868 [PubMed - indexed for MEDLINE]Related articles

Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.

Klerkx AH, El Harchaoui K, van der Steeg WA, Boekholdt SM, Stroes ES, Kastelein JJ, Kuivenhoven JA.

Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):706-15. Epub 2006 Jan 26. Review.PMID: 16439711 [PubMed - indexed for MEDLINE]Related articlesFree article

Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia.

Bisoendial RJ, Hovingh GK, El Harchaoui K, Levels JH, Tsimikas S, Pu K, Zwinderman AE, Kuivenhoven JA, Kastelein JJ, Stroes ES.

Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):e133-4. No abstract available. PMID: 16127020 [PubMed - indexed for MEDLINE]Related articlesFree article